Efficacy and Safety Evaluation of Febuxoat in the Treatment of Chronic Kidney Disease with Hyperuricemia
Objective To evaluate the efficacy and safety of febuxoat in the treatment of chronic kidney disease(CKD)with hyperuricemia(HUA).Methods A total of sixty-two patients with CKD and HUA treated in Lianshui County People's Hospital from January 2022 to December 2023 were objectively selected and divided into control group(allo-purine treatment,thirty-one cases)and intervention group(febulistat treatment,thirty-one cases)according to differ-ent treatment methods.The efficacy,uric acid level and incidence of adverse reactions of the two groups were com-pared.Results The intervention group total effective was 96.77%(30/31)higher than 74.19%(23/31)of the control group,the difference was statistically significant(χ2=4.679,P<0.05).After 1 month and 3 months of treatment,the uric acid levels in the intervention group were better than those in the control group,the differences were statistically significant(both P<0.05).The total adverse reaction rate of intervention group was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion Febuxostat is effective in the treatment of CKD pa-tients with HUA,with high safety and low incidence of adverse reactions.
NETL
NSTL
万方数据
